1. AGENT III: 12 week results
415 patients with CCS Class 2-4 angina not in need of urgent revascularization
Ad5FGF-4 gene
Adenoviral intracoronary infusion of human angiogenic fibroblast growth factor-4 (FGF-4)
Placebo
Low-dose
High-dose
Primary Endpoint:
Exercise tolerance test time compared with baseline at 12 weeks, 6 months and 1 year.
Secondary Endpoints:
Time to number of patients with coronary events and death at 12 months
Time to ST depression, angina, and quality of life parameters
Presented at TCT 2004

2. AGENT III Trial: 12 week results
Mean change in exercise duration from baseline to 12 weeks
p=ns
The 12-week results show no difference between the three groups in the primary endpoint – mean change in exercise duration from baseline
seconds
TCT 2004

3. AGENT III: 12-week results
415 people with stable angina were randomized to receive placebo or a low- or high-dose intracoronary infusion of an adenoviral gene for fibroblast growth factor-4 (FGF-4) before the trial was stopped earlier this year by the data safety and monitoring board
The 12-week results show no difference between the three groups in the primary endpoint – mean change in exercise duration from baseline.
TCT 2004